| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
|
|
|
|||||||
|
|||||||||
Statements of interest
The following authors declared a statement of interest concerning papers published in volume 29 of the ERJ.
A
Back to Top
C. Advenier. This author's study was funded by Novartis Pharma. DOI: 10.1183/09031936.00032806
M.J. Abramson served on the Scientific Advisory Committee for the Australian Asthma Study, which was sponsored by GlaxoSmithKline. The author has also previously received travel assistance from AstraZeneca DOI: 10.1183/09031936.00080906.
A. Aliverti. The university at which the author's study was conducted (Politecnico di Milano University, Milan, Italy) owns a patent on the detection of expiratory flow limitation. DOI: 10.1183/09031936.00038006.
S. Andreas received reimbursement for attending a symposium and received funds for research. He also received lecture fees from AstraZeneca, Boehringer-Ingelheim, Novartis, Weinmann and Respironics. The study (which appears in the June 2007 issue of the European Respiratory Journal) was supported by a grant from Respironics. DOI: 10.1183/09031936.00037106
S.M. Arend was invited as an expert by the Centers for Disease Control (Atlanta, GA, USA) to attend a meeting held in Atlanta in July 2005, during which guidelines on the use of QuantiFERON®-TB Gold were drafted. This included the presentation of studies in which the assay, as described in the manuscript that appears in the June 2007 issue of the European Respiratory Journal, was used. DOI: 10.1183/09031936.00117506
B
Back to Top
T.R. Bai has received fees for speaking and consulting. DOI: 10.1183/09031936.00112606
P.J. Barnes has received research funding from and given lectures on behalf of AstraZeneca and GlaxoSmithKline, both of which market combination inhalers. DOI: 10.1183/09031936.00080306
P.J. Barnes. The Exacerbations of COPD meeting (held in Como, Italy, in April 2005) summarised in the author’s review article presented in the June issue of the European Respiratory Journal was sponsored by an educational grant from AstraZeneca. The sponsors had no input into the structure of the meeting or the preparation of that article. DOI: 10.1183/09031936.00109906
K.M. Beeh received compensation for serving on an advisory board for Novartis, Germany. The author has participated as a speaker in scientific meetings or courses organised and financed by various pharmaceutical companies (Boehringer, Novartis, Pfizer, Fujisawa and Merck Sharpe & Dohme) in 2003, 2004 and 2005. K.M. Beeh has received fees for speaking at a conference symposium sponsored by Novartis in 2005. The institution at which the author is currently employed has received compensation for participating in multicentre clinical trials in 2004, 2005 and 2006 from several companies (AstraZeneca, Boehringer, Novartis, GlaxoSmithKline, Revotar Biopharmaceuticals, EpiGenesis, Corus Pharma, Allmirall Prodesfarma, Merck Sharp & Dohme and Fujisawa). The author also has been reimbursed for travel expenses by Novartis, Boehringer, Merck Sharpe & Dohme and Pfizer for attending several conferences. DOI: 10.1183/09031936.00060006
J. Behr has received fees for speaking and consulting from Actelion Pharmaceutics. The author has also received reimbursement for travel to the ERS congress from Actelion Pharmaceutics DOI: 10.1183/09031936.00149205.
M.G. Belvisi has received an educational grant from GlaxoSmithKline and Novartis. The author has also acted as a consultant for GlaxoSmithKline. DOI: 10.1183/09031936.00101006
T. Bernhardt has been employed by an organisation that may gain or lose financially from the results of this author's work. DOI: 10.1183/09031936.00047306.
J. Bion was President of the European Society of Intensive Care Medicine, declared European Union grants for CoBaTrICE and GenOSept projects, was chair of independent data and safety monitoring committees for Orion (Espoo, Finland) and for Alliance Pharmaceuticals (Chippenham, UK) and declared travel grants from Draeger (Luebeck, Germany), Pfizer (Tadworth, UK) and Wyeth (Maidenhead, UK). DOI: 10.1183/09031936.00010206
S.S. Birring is a co-author of the Leicester Cough Questionnaire. DOI: 10.1183/09031936.00101006
A. Blau. The author’s study (which appears in the June 2007 issue of the European Respiratory Journal) was supported by a grant from Respironics. DOI: 10.1183/09031936.00037106
J. Boe has received funds for research from the Norwegian Foundation for Health and Rehabilitation. This author's manuscript was submitted to the European Respiratory Journal in 2005. DOI: 10.1183/09031936.00044805.
J. Boe has 135 B- shares in AstraZeneca PLC. The author’s study (which appears in the June 2007 issue of the European Respiratory Journal) was funded by a grant from AstraZeneca. DOI: 10.1183/09031936.00128806
J. Börgel. The author’s study (which appears in the June 2007 issue of the European Respiratory Journal) was supported by a grant from Respironics. DOI: 10.1183/09031936.00037106
A.W.J. Bossink is a member of the advisory board of Oxford Immunotec Ltd, Oxford, UK. DOI: 10.1183/09031936.00117506
L-P. Boulet has received fees for attending symposia, speaking, organising education, research and consulting. Specifically, he has received: honoraria to attend Advisory Boards for AstraZeneca, Altana, GlaxoSmithKline, Merck Frosst and Novartis; lecture fees from 3M, AstraZeneca, GlaxoSmithKline, Novartis and Merck Frosst; sponsorship for basic research from 3M, Altana, AstraZeneca and Merck Frosst; funding for participating in multicentre studies for the treatment of asthma from 3M, Altana, AsthmaTx, AstraZeneca, Boehringer Ingelheim, Dynavax, Genentech, GlaxoSmithKline, IVAX, Merck Frosst, Novartis, Roche, Schering and Topingen; and support for the production of educational materials from AstraZeneca, GlaxoSmithKline and Merck Frosst. DOI: 10.1183/09031936.00132406.
P.H. Brekke’s travel to the American Thoracic Society Congress was funded by GlaxoSmithKline. DOI: 10.1183/09031936.00106406.
V. Brusasco has received: €4,650 from GSK for a manuscript copyright; €11,625 in 2003, €11,625 in 2004 and €12,500 in 2005–2006 for serving on an advisory board for Altana; €5,000 in 2002, €5,000 in 2003, €3,000 in 2004 and €3000 in 2005 from Lofarma for consultancy; €5,750 in 2004 from MSD for consultancy; £960 in 2006 from GSK for consultancy; €1,000 in 2002 for speaking at a meeting organised by Sigma-Tau; €1,875 in 2002, €6,000 in 2004, €11,500 in 2005 and €3,325 for speaking at conferences sponsored by Boehringer Ingelheim; €2,500 for speaking at a meeting organised by Chiesi; and €2,500 for consultancy in a study sponsored by Chiesi. V. Brusasco’s institution received €15,000 in 2003 as an unrestricted research grant from Altana and has participated in several multicentre clinical trials financed by pharmaceutical companies (Chiesi, MSD, Boehringer Ingelheim, GSK and Novartis). DOI: 10.1183/09031936.00112606
C
Back to Top
P.M.A. Calverley. The university at which the author’s study was conducted (Politecnico di Milano University, Milan, Italy) owns a patent on the detection of expiratory flow limitation. DOI: 10.1183/09031936.00038006.
R. Cameron has been an employee of Novartis since April 1996. DOI: 10.1183/09031936.00060006
B. Celli received consultancy fees from Ortho Biotech. DOI: 10.1183/09031936.00137106
B.R. Celli. The Exacerbations of COPD meeting (held in Como, Italy, in April 2005) summarised in the author’s review article presented in the June 2007 issue of the European Respiratory Journal was sponsored by an educational grant from AstraZeneca. The sponsors had no input into the structure of the meeting or the preparation of that article. DOI: 10.1183/09031936.00109906
N.I. Chaudhary was, at the time of conducting the study, an employee of Boehringer Ingelheim Pharma GmbH & Co. KG. DOI: 10.1183/09031936.00152106
K.F. Chung has: received reimbursement from Altana and Novartis for attending respiratory conferences; received renumeration for attending advisory boards organised by GlaxoSmithKline, AstraZeneca and Novartis; has collaborated with Vivometrics for evaluation of LifeShirt as a cough monitor; and has obtained unrestricted research funds from GlaxoSmithKline. DOI: 10.1183/09031936.00101006
A. Connors declared being a Veterans Administration DSMB on a randomised controlled trial, a co-investigator on a National Institutes of Health (NIH) grant, having support from the National Heart, Lung and Blood Institute for the Acute Respiratory Distress Syndrome Network (ARDSNet), but having no support from industry. DOI: 10.1183/09031936.00010206
C. Cote received a consultant fee and a small research grant from Ortho Biotech. DOI: 10.1183/09031936.00137106
H.O. Coxson received CAN$11,000 in 2005 for serving on an advisory board for GlaxoSmithKline. In addition, H.O. Coxson is the co-investigator on two multicentre studies sponsored by GlaxoSmithKline and has received travel expenses to attend meetings related to the project. The author has three contract service agreements with GlaxoSmithKline to quantify the computed tomography scans in subjects with chronic obstructive pulmonary disease. A percentage of H.O. Coxson’s salary between 2003 and 2006 (US$15,000 per year) derives from contract funds provided to a colleague, P. D. Pare, by GlaxoSmithKline, for the development of validated methods to measure emphysema and airway disease using computed tomography. H.O. Coxson is the co-investigator on a Canadian Institutes of Health–Industry (Wyeth) partnership grant. There is no financial relationship between any industry and the study that appears in the June 2007 issue of the European Respiratory Journal. DOI: 10.1183/09031936.00039807
D
Back to Top
R.L. Dellacà. The university at which the author’s study was conducted (Politecnico di Milano University, Milan, Italy) owns a patent on the detection of expiratory flow limitation. DOI: 10.1183/09031936.00038006.
E. Derom received $1,950 in 2002, $2,280 in 2003 and $2,495 in 2004 for serving on an advisory board for GlaxoSmithKline. The author also received $106,930 for the period 2003–2005 from Altana Pharma, $5,890 for the period 2003–2005 from GlaxoSmithKline, $100,280 in 2004 from SGSBiopharma and $163,400 in 2003 from Novartis as research grants for participating in clinical trials. E. Derom received a grant from AstraZeneca to allow him to attend the ATS 2004 congress and from Altana Pharma to attend the ERS 2005 congress. DOI: 10.1183/09031936.00060006
M. Dreher has been reimbursed by a local provider of home ventilators, Werner und Müller Medizintechnik, Germany, for attending the annual German conferences on home mechanical ventilation in 2003, 2005 and 2006, and for attending the 10th International Conference on Home Mechanical Ventilation 2005 in Lyon, France. DOI: 10.1183/09031936.00075806
H.W. Duchna. The author’s study (which appears in the June 2007 issue of the European Respiratory Journal) was supported by a grant from Respironics. DOI: 10.1183/09031936.00037106
N. Duffy. The university at which the author’s study was conducted (Politecnico di Milano University, Milan, Italy) owns a patent on the detection of expiratory flow limitation. DOI: 10.1183/09031936.00038006.
E
Back to Top
F
Back to Top
L.M. Fabbri has received funds for research, consulting fees, lecture fees and reimbursements for travel expenses for attending symposiums/meetings from Chiesi Farmaceutici, Boehringer Ingelheim, AstraZeneca, GlaxoSmithKline, Pfizer, Roche, Altana, Novartis, Schering-Plough and Menarini DOI: 10.1183/09031936.00095906.
K.O. Fagerström has received fees for speaking and consulting, and reimbursement for attending symposia. He holds stocks in an organisation that may gain or lose financially: the company is called NicoNovum and it develops nicotine replacement products. DOI: 10.1183/09031936.00060806.
R.A. Fairhurst is an employee of Novartis Pharma UK Ltd and has stock in this organisation. DOI: 10.1183/09031936.00032806
I. Fietze. The author’s study (which appears in the June 2007 issue of the European Respiratory Journal) was supported by a grant from Respironics. DOI: 10.1183/09031936.00037106
G
Back to Top
H-A. Ghofrani has received fees for speaking and consulting from Actelion Pharmaceutics DOI: 10.1183/09031936.00149205.
R.E. Girgis has received: consulting and speaker honoraria from Encysive Pharmaceuticals; consulting honoraria from Cotherix; speaker honoraria from Actelion; and clinical research support from Encysive, Pfizer, United Therapeutics, Myogen, Actelion and Lilly-ICOS. DOI: 10.1183/09031936.00081706
A. Günther has received lecture fees and reimbursement for attending a symposium by Actelion DOI: 10.1183/09031936.00149205.
H
Back to Top
I.P. Hall has received research support and travel cost supports (for the European Respiratory Society Congress 2006) from Novartis Pharma. The research support was provided for a project on novel long-acting beta-agonist. DOI: 10.1183/09031936.00088206
J.R. Harris has received funds for research from the Norwegian Foundation for Health and Rehabilitation. This author’s manuscript was submitted to the European Respiratory Journal in 2005. DOI: 10.1183/09031936.00044805.
D. Hartl has been employed by an organisation that may gain or lose financially from the results of this author’s work. DOI: 10.1183/09031936.00047306.
M. Herridge declared grants from the Physicians' Services Incorporated Foundation, the Ontario Thoracic Society and the NIH but no consulting fees. DOI: 10.1183/09031936.00010206
M. Higgins has been employed by Novartis since November 2001 and holds shares in the company. DOI: 10.1183/09031936.00060006
F. Hilberg was, at the time of conducting the study, an employee of Boehringer Ingelheim Pharma GmbH & Co. KG. DOI: 10.1183/09031936.00152106
I
Back to Top
J
Back to Top
K
Back to Top
F. Kanniess received contributions for the conduct of clinical trials or educational grants from GSK, Epigenesis, ALTANA, AstraZeneca, Allmiral Prodesfarma, Boehringer Ingelheim, Schering-Plough, Astellas and ONO. DOI: 10.1183/09031936.00060006
J.A. Kastelik has received speaker honoraria or reimbursement for attending symposia for AstraZeneca, GlaxoSmithKline, Pfizer, Boehringer-Ingelhein and Schering Plough. The author has also received an educational grant from Altana Pharma. DOI: 10.1183/09031936.00101006
G.G. King has received, over the past 5 years, various travel sponsorships from AstraZeneca and GlaxoSmithKline for travel and accommodation to attend international scientific meetings. The value of these sponsorships is approximately from AUS$10,000 to AUS$15,000 per year. A proportion of G.G. King’s research work is conducted at the Woolcock Institute of Medical Research, which receives unrestricted grants from Boehringer Ingelheim, AstraZeneca, GlaxoSmithKline and Vita Medical, and which also has a consultancy agreement with Pfizer, Boehringer Ingelheim, AstraZeneca and GlaxoSmithKline for which G.G. King provides consultancy services related to asthma and COPD. G.G. King’s research group receives a proportion of the grants and monies that arise from those companies, as part of a general allocation of those funds for research purposes across all research groups of the Woolcock Institute of Medical Research. DOI: 10.1183/09031936.00112606
J. Kongerud has received funds for research from the Norwegian Foundation for Health and Rehabilitation. This author’s manuscript was submitted to the European Respiratory Journal in 2005. DOI: 10.1183/09031936.00044805.
I. Koper. The author’s study (which appears in the June 2007 issue of the European Respiratory Journal) was supported by a grant from Respironics. DOI: 10.1183/09031936.00037106
M. Korppi is a member of the consultant board for respiratory syncitial virus infections in children of Abbott Oy, Finland. DOI: 10.1183/09031936.00001907
N.G. Koulouris. The university at which the author’s study was conducted (Politecnico di Milano University, Milan, Italy) owns a patent on the detection of expiratory flow limitation. DOI: 10.1183/09031936.00038006.
S.L. Kunkel has received a speaking fee from the University of Maryland (Maryland, MD, USA) and the University of California (USA). He has also consulted for Novartis and Pharmacopeia. DOI: 10.1183/09031936.00122806
L
Back to Top
I. Leconte is an Actelion employee who own stocks from this company DOI: 10.1183/09031936.00149205.
C-G. Löfdahl has: been paid for lectures by AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKline and Pfizer; taken part in ad hoc advisory boards for the same companies; and has had institutional support from AstraZeneca, Boehringer-Ingelheim and GlaxoSmithKline. The author’s study (which appears in the June 2007 issue of the European Respiratory Journal) was funded by a grant from AstraZeneca. DOI: 10.1183/09031936.00128806
M.B. Lund has received funds for research from the Norwegian Foundation for Health and Rehabilitation. This author’s manuscript was submitted to the European Respiratory Journal in 2005. DOI: 10.1183/09031936.00044805.
M
Back to Top
F.J. Martinez has received funds for research. DOI: 10.1183/09031936.00122806
W. Mitzner has received fees for speaking, organising education, research and as a member of staff. DOI: 10.1183/09031936.00112606
S.H. Mody is currently an employee of Ortho Biotech Clinical Affairs, LLC and owns stock in Johnson & Johnson, its parent company. DOI: 10.1183/09031936.00137106
M. Molimard. The author's study was funded by Novartis Pharma. DOI: 10.1183/09031936.00032806
A.H. Morice has received research support from Profile Respiratory Systems Ltd, Altana Pharma, AstraZeneca, GlaxoSmithKline, Schering Plough Research and Novartis. The author has also received speaker honoraria from AstraZeneca, Altana Pharma, IVAX Pharmaceuticals, GlaxoSmithKline, ReckittBenckiser Healthcare and Novartis. Advisory committee honoraria have been received from Proctor and Gamble Healthcare and GlaxoSmithKline. Sponsorship to attend international meetings was also provided by IVAX Pharmaceuticals and Boehringer-Ingelheim. DOI: 10.1183/09031936.00101006
H. Müllerova has competing financial interests. The author is an employee of a pharmaceutical company: GlaxoSmithKline R&B. DOI: 10.1183/09031936.00092506
J. Müller-Quernheim received a research grant from Boehringer Ingelheim Pharma GmbH & Co. KG as a part of a research collaboration. DOI: 10.1183/09031936.00152106
T.M. Murphy has received educational grants from GlaxoSmithKline, AstraZeneca, Merck, Sepracor, Genentech and Novartis. The author has also received consulting fees from AstraZeneca and Merck, and speaking fees from AstraZeneca and Merck. DOI: 10.1183/09031936.00112606
N
Back to Top
H. Nakano has filed a patent entitled "System and method for automated detection of apnea and hypopnea" DOI: 10.1183/09031936.00091206.
E. Naline. The author's study was funded by Novartis Pharma. DOI: 10.1183/09031936.00032806
G. Nicolini is an employee of the company that was sponsor of the study (Chiesi Farmaceutici) DOI: 10.1183/09031936.00095906.
W. Nystad has received funds for research from the Norwegian Foundation for Health and Rehabilitation. This author’s manuscript was submitted to the European Respiratory Journal in 2005. DOI: 10.1183/09031936.00044805.
O
Back to Top
T. Omland has received fees for speaking, research and consulting. He has received: honoraria from Roche Diagnostics, Bayer Diagnostics and Abbott Laboratories; consultancy fees from Roche Diagnostics; and research support from Roche Diagnostics and Abbott laboratories, manufacturers of assays for tropinin. DOI: 10.1183/09031936.00106406.
T.H.M. Ottenhoff received funds for a member of staff and has been an expert witness on the subject of the study presented in the June 2007 issue of the European Respiratory Journal. The author also obtained grants for standard research projects funded by the European Union or the Dutch Government. DOI: 10.1183/09031936.00117506
P
Back to Top
P.L. Paggiaro has received approximately €50,000 in the last 5 years as a fee for speaking for GSK, AstraZeneca, MSD, Novartis, Menarini, Boehringer Ingelheim and Pfizer. The author has also received €45,000 from Altana Pharma in the last 5 years for research DOI: 10.1183/09031936.00095906.
A. Papi has received funds for research, fees for speaking, reimbursements for attending symposiums and fees for consulting from Chiesi Farmaceutici DOI: 10.1183/09031936.00095906.
P.D. Paré is the principle investigator of a project funded by GSK to develop CT-based algorithms to quantitative emphysema and airway disease in COPD. With collaborators, the author has received ~$300,000 to develop and validate these techniques. The funds have been applied solely to the research to support programmes and technicians. P.D. Paré is also PI of a Merck Frost-supported research programme to investigate gene expression in the lungs of patients who have COPD. He and collaborators have received ~$200,000 for this project. These funds have supported the technical personnel and expendables involved in the project. DOI: 10.1183/09031936.00112606
J.E. Park was, at the time of conducting the study, an employee of Boehringer Ingelheim Pharma GmbH & Co. KG. DOI: 10.1183/09031936.00152106
I.D. Pavord has received lecture fees of less than £5,000 from GSK and AstraZeneca, and holds an industry-sponsored grant of £250,000 from GSK. DOI: 10.1183/09031936.00146306
R. Pearl was on the Advisory Board for Hutchinson Technology (Hutchinson, MN, USA) and declared an honorarium from Johnson and Johnson (New Brunswick, NJ, USA). DOI: 10.1183/09031936.00010206
A. Pedotti. The university at which the author’s study was conducted (Politecnico di Milano University, Milan, Italy) owns a patent on the detection of expiratory flow limitation. DOI: 10.1183/09031936.00038006.
P.P. Pompilio. The university at which the author’s study was conducted (Politecnico di Milano University, Milan, Italy) owns a patent on the detection of expiratory flow limitation. DOI: 10.1183/09031936.00038006.
D.S. Postma has received grants for research purposes from AstraZeneca, GSK (two multicentre studies) and Altana, in local single centre research on asthma and COPD. This author received €10,000 in 2002-2004 for serving on an advisory board for Altana. D.S. Postma serves as a consultant to AstraZeneca, Altana, Centocor and GSK. The author has also been reimbursed to attend international meetings by AstraZeneca, Altana, Centocor and GSK. The author's institute has received an unrestricted educational grant from GSK. DOI: 10.1183/09031936.00124506
D.S. Postma received grants for research purposes from AstraZeneca, GlaxoSmithKline (for two multicentre studies) and Altana for local single-centre research on asthma and COPD. The author received €10,000 in 2002–2004 for serving on an advisory board for Altana, and serves as a consultant to AstraZeneca, Altana, Centocor and GlaxoSmithKline. D.S. Postma has been reimbursed for attending international meetings by AstraZeneca, Altana, Centocor and GlaxoSmithKline. Her institute has received an unrestricted educational grant from GlaxoSmithKline. D.S. Postma has received: €10,000 for consultancy to Altana; €5,000 for serving on an advisory board for GlaxoSmithKline; and €5,000 for serving on the advisory board for AstraZeneca. The following industry-spondored grants have been received or are pending: €100,000 from AstraZeneca; €100,000 from GlaxoSmithKline; €100,000 from Altana. The author’s study (which appears in the June 2007 issue of the European Respiratory Journal) was funded by a grant from AstraZeneca. DOI: 10.1183/09031936.00128806
A. Prasse received a research grant from Boehringer Ingelheim Pharma GmbH & Co. KG as a part of a research collaboration. DOI: 10.1183/09031936.00152106
R. Prenzel. The author’s study (which appears in the June 2007 issue of the European Respiratory Journal) was supported by a grant from Respironics. DOI: 10.1183/09031936.00037106
N.B. Pride has been a member of an advisory board for GlaxoSmithKline and has received fees for three related talks. The author’s study (which appears in the June 2007 issue of the European Respiratory Journal) was funded by a grant from AstraZeneca. DOI: 10.1183/09031936.00128806
Q
Back to Top
R
Back to Top
K.F. Rabe received fees for consultancy. He is consultant to Hoffman La-Roche. DOI: 10.1183/09031936.00056206
J.H.C. Reiber received fees for consultancy. He is consultant to Medis Medical Systems, Leiden, the Netherlands. DOI: 10.1183/09031936.00056206
G.J. Roth was, at the time of conducting the study, an employee of Boehringer Ingelheim Pharma GmbH & Co. KG. DOI: 10.1183/09031936.00152106
S. Roux is an Actelion employee who owns stocks from this company DOI: 10.1183/09031936.00149205.
S
Back to Top
M.J. Sanderson has received research, travel and educational funds from Sepracor Inc. DOI: 10.1183/09031936.00112606
S. Schädlich. The author’s study (which appears in the June 2007 issue of the European Respiratory Journal) was supported by a grant from Respironics. DOI: 10.1183/09031936.00037106
J. Schmitt. The author’s study (which appears in the June 2007 issue of the European Respiratory Journal) was supported by a grant from Respironics. DOI: 10.1183/09031936.00037106
A. Schnapp was, at the time of conducting the study, an employee of Boehringer Ingelheim Pharma GmbH & Co. KG. DOI: 10.1183/09031936.00152106
R. Schulz. The author’s study (which appears in the June 2007 issue of the European Respiratory Journal) was supported by a grant from Respironics. DOI: 10.1183/09031936.00037106
W. Seeger received reimbursement: from Altana Pharma AG for participation in the ATS Congress in 2004; and from Schering AG for the Ventavis® Launch Symposium (Madeira) in 2003. The author has also received speaking fees from Schering AG for taking part in an Expert Round Table in Pulmonary Hypertension and for taking part in the Ventavis® Launch Symposium. W. Seeger has received: reimbursement from Pfizer AG for taking part in the 110th Annual Meeting of the German Society of Internal Medicine; and funds for research for clinical studies from Altana Pharma AG, Actelion, Schering AG, Myogen Inc. and Lung Rx. The author also received a fee from Altana Pharma AG for organising education for a graduate college and consulting fees from Altana Pharma AG, Lung Rx and Schering AG DOI: 10.1183/09031936.00149205.
H. Silverman was a member of DSMB, Broncus Technologies Inc. (Mountain View, CA, USA), declared an Ethics Consultant meeting travel grant from Boehringer Ingelheim Pharmaceuticals Inc. (Ingelheim, Germany) and a Research Ethics Training Grant from NIH. DOI: 10.1183/09031936.00010206
J.A. Smith is an inventor on a patent filed by South Manchester University Hospitals Trust (Manchester, UK), describing a novel method for automated cough detection. The Trust also has a licence agreement with a medical devices company to develop a commercial cough monitor. DOI: 10.1183/09031936.00101006
J. Solway has received, since 2001, consulting fees or honoraria for participating in expert or advisory panels from Tanox, Merck, Critical Concepts, Wyeth and Aventis Pharmaceutical Companies. The University of Chicago Asthma Center, which J Solway directs, has received educational grants from Glaxo, Merck and AstraZeneca. The author has received research funding from Glaxo, and has received travel support and honoraria to present at the Asthma and Smooth Muscle Symposia in Fukuoka, Japan, from Ono Pharmaceuticals. DOI: 10.1183/09031936.00112606
G. Stähler has received a fee for speaking DOI: 10.1183/09031936.00149205.
M. Stanchina received grant support/honoraria from Respironics Inc. (Murrysville, PA, USA) and Boehringer Ingelheim Pharmaceuticals, Inc. DOI: 10.1183/09031936.00010206
N.L. Stephens has received an operating grant from the Philip Morris Extramural Research Foundation. DOI: 10.1183/09031936.00112606
A. Stewart received grants from the Tobacco Foundation of Australia in 1958. He is an employee and stockholder of Cryptopharma, a company with an interest in developing drugs to reduce airway and lung remodelling. DOI: 10.1183/09031936.00053506.
A.G. Stewart was the recipient of an Australian Tobacco Research Foundation Fellowship in 1984. DOI: 10.1183/09031936.00112606
B.C. Stoel received fees for consultancy. He is a consultant of BioImaging Technologies in Leiden, the Netherlands. He is also a consultant to Roche, Talecris and ZLB Behring concerning lung densitometry as the outcome parameter for testing drugs for emphysema. DOI: 10.1183/09031936.00056206
J. Stolk received fees for consulting and has acted as an expert witness on the subject of the study (published in the June 2007 issue of the European Respiratory Journal). The author is a consultant of BioImaging Technologies in Leiden, the Netherlands, and is involved in clinical trials in which lung densitometry is the primary outcome parameter of the study. J. Stolk is also a consultant for Hoffman La-Roche and Octapharma and gave advice on lung densitometry as the outcome parameter for detection of the effect of drugs for emphysema. DOI: 10.1183/09031936.00056206
J.H. Storre has been reimbursed from a local provider of home ventilators, Werner und Müller Medizintechnik, Germany, for attending the annual German conferences on home mechanical ventilation in 2003, 2005 and 2006, and for attending the 10th International Conference on Home Mechanical Ventilation 2005 in Lyon, France. The author also received a speaking fee of €500 in 2005 from Werner und Müller Medizintechnik. DOI: 10.1183/09031936.00075806
T
Back to Top
T. Tanigawa serves as CEO of the Somnonics Co. Ltd which aims to develop a screening for sleep apnoea syndrome in the general population and was established with the support of the University of Tsukuba DOI: 10.1183/09031936.00091206.
S. Tasci. The author’s study (which appears in the June 2007 issue of the European Respiratory Journal) was supported by a grant from Respironics. DOI: 10.1183/09031936.00037106
M. Tatar has received a bronze sponsorship from the European Respiratory Society (ERS) to attend an Annual ERS Meeting. DOI: 10.1183/09031936.00101006
A. Thorén is a full-time employee of AstraZeneca. The author holds stocks or shares in an organisation that may in any way gain or lose financially from the results of the study. The author’s study (which appears in the June 2007 issue of the European Respiratory Journal) was funded by a grant from AstraZeneca. DOI: 10.1183/09031936.00128806
P. Tønnesen has received fees for speaking and consulting, has acted as a consultant and has been paid for talks given for companies producing and selling smoking cessation drugs. DOI: 10.1183/09031936.00060806.
A. Trifilieff received reimbursement for attending a symposium and for research. This author had also acted as an expert witness on the subject of the study. A. Trifilieff is an employee of Novartis Pharma and has stock in Novartis. DOI: 10.1183/09031936.00032806
U
Back to Top
V
Back to Top
A. van As is a former employee of Novartis (until 31st August 2006) and owned Novartis stock until then. DOI: 10.1183/09031936.00060006
W
Back to Top
J.A. Wedzicha has received research grant funding and honoraria for attending meetings from GlaxoSmithKline. DOI: 10.1183/09031936.00092506
T. Welte has received fees totalling €300,000 for talks on national symposia from RESMED. The author has also received a research grant of €100,000 from RESMED and a grant of €100,000 from Tyco Int. for organisation of an international multicentre study. DOI: 10.1183/09031936.00010206
R. West has received funds for research, consulting, members of staff, speaking and for organising education. He has worked for manufacturers of smoking cessation products, has been an expert witness on whether nicotine patches are VAT exempt and shares a patent for a novel nicotine-deliverable device. DOI: 10.1183/09031936.00060806.
W. Windisch was reimbursed by Breas Medical AB (Molnlycke, Sweden) for attending the annual ERS conferences between 2001 and 2005. This author has also been reimbursed from the local provider of home ventilators Werner and Müller Medizintechnik, Germany, for attending the annual German conferences on home mechanical ventilation between 2001 and 2006. W. Windisch received a speaking fee of €1,000 in 2005 from Werner und Müller Medizintechnik. DOI: 10.1183/09031936.00075806
X
Back to Top
Y
Back to Top
Z
Back to Top
M.D. Zilberberg is an employee of Ortho Biotech, as well as a shareholder of Johnson & Johnson, its parent company. DOI: 10.1183/09031936.00137106
G. Zissel received a research grant from Boehringer Ingelheim Pharma GmbH & Co. KG as a part of a research collaboration. DOI: 10.1183/09031936.00152106
Back to Top
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |